Experimental Alzheimer’s Pill Boosts the Brain’s Cleanup System

Feb 11, 2026 | Clinical Trials

Image Source: Stock Image
Written by: Contributor
On behalf of: Life Science Daily News

Wouldn’t life be easier if someone was there to keep on top of chores around the house? That’s the idea behind Anavex Life Sciences’ experimental, once-daily pill blarcamesine, which is being tested in patients in the early stages of Alzheimer’s disease. This drug aims to activate the brain’s built-in clean-up service to reduce the accumulation…

Explorer – Monthly Subscription Membership Required

You must be a Explorer – Monthly Subscription member to access this content.

Join Now

Already a member? Log in here
    References: None.

    Articles that may be of interest

    Panthera Biopartners Expands European Footprint

    Panthera Biopartners Expands European Footprint

    Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...

    read more
    Clinical Trials Roundup | 17 April 2026

    Clinical Trials Roundup | 17 April 2026

    Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...

    read more
    Clinical Trials Roundup | 10 April 2026

    Clinical Trials Roundup | 10 April 2026

    Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...

    read more

    Articles that may be of interest

    Panthera Biopartners Expands European Footprint

    Panthera Biopartners Expands European Footprint

    Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...

    read more
    Clinical Trials Roundup | 17 April 2026

    Clinical Trials Roundup | 17 April 2026

    Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...

    read more
    Clinical Trials Roundup | 10 April 2026

    Clinical Trials Roundup | 10 April 2026

    Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...

    read more